Lianbo Yu

11.2k total citations · 4 hit papers
155 papers, 7.6k citations indexed

About

Lianbo Yu is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Lianbo Yu has authored 155 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 40 papers in Immunology and 37 papers in Oncology. Recurrent topics in Lianbo Yu's work include MicroRNA in disease regulation (22 papers), Cancer-related molecular mechanisms research (15 papers) and Immune Cell Function and Interaction (11 papers). Lianbo Yu is often cited by papers focused on MicroRNA in disease regulation (22 papers), Cancer-related molecular mechanisms research (15 papers) and Immune Cell Function and Interaction (11 papers). Lianbo Yu collaborates with scholars based in United States, China and Argentina. Lianbo Yu's co-authors include Julie W. Reeser, Sameek Roychowdhury, Jharna Miya, Melanie A. Krook, Russell Bonneville, Esko A. Kautto, S. Patrick Nana‐Sinkam, Michele R. Wing, Hui‐Zi Chen and Clay B. Marsh and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Lianbo Yu

151 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Detection of microRNA Expression in Human Peripheral Blood Microvesicles

2008 1.2k citations Xiaoli Zhang, Lianbo Yu et al. profile →
Landscape of Microsatellite Instability Across 39 Cancer Types

2017 1.0k citations Russell Bonneville, Melanie A. Krook et al. profile →
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver

2012 623 citations Jianhua Yu, Lianbo Yu et al. profile →
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

2016 401 citations Lianbo Yu, Michael C. Ostrowski et al. profile →

Peers

Countries citing papers authored by Lianbo Yu

Since Specialization

Citations

This map shows the geographic impact of Lianbo Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lianbo Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lianbo Yu more than expected).

Fields of papers citing papers by Lianbo Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lianbo Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lianbo Yu. The network helps show where Lianbo Yu may publish in the future.

Co-authorship network of co-authors of Lianbo Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Lianbo Yu. A scholar is included among the top collaborators of Lianbo Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lianbo Yu. Lianbo Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer 2025 ·Cancer Immunology Research ·Emily Schwarz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lianbo Yu, Gregory K. Behbehani, Timothy P. Cripe, William E. Carson	2
2	807MO High efficacy and safety of interleukin-6-knockdown CD19-targeted CAR-T cells in relapsed/refractory B-ALL patients 2024 ·Annals of Oncology ·Lianbo Yu, Lijuan Kang, Songtao Xue, Xiaolong Tang, Xiaoding Lou, Qian Chen, Wenfeng Gong, Mingfang Xu, Hui Zhou, (unknown), (unknown), Ming Li, Na Xu, Zhenhai Yu, Sharon Chen, Hao Qiu, Haiqing Dai, Yan Xu, Dayong Wu	1
3	A novel goldfish orthotopic xenograft model of hepatocellular carcinoma developed to evaluate antitumor drug efficacy 2024 ·Fish & Shellfish Immunology ·(unknown), (unknown), Jing Zeng, Lianbo Yu, (unknown), (unknown)	1
4	Stromal p53 Regulates Breast Cancer Development, the Immune Landscape, and Survival in an Oncogene-Specific Manner 2022 ·Molecular Cancer Research ·Jinghai Wu, Xin Liu, Julie W. Reeser, Anthony J. Trimboli, Thierry Pécot, Gina M. Sizemore, Shan K. Naidu, Soledad Fernández, Lianbo Yu, Michael Hallett, Morag Park, Gustavo Leone, Blake E. Hildreth, Michael C. Ostrowski	5
5	Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis 2022 ·Kidney International ·Samir V. Parikh, Ana Malvar, Huijuan Song, John P. Shapiro, Juan M. Mejía‐Vilet, Isabelle Ayoub, Salem Almaani, Sethu M. Madhavan, Valeria Albertón, (unknown), Bruno Lococo, Anjali A. Satoskar, Jianying Zhang, Lianbo Yu, Paolo Fadda, Michael T. Eadon, Dan Birmingham, Latha P. Ganesan, Wael N. Jarjour, Brad H. Rovin	27
6	Amino Acid Nanofibers Improve Glycemia and Confer Cognitive Therapeutic Efficacy to Bound Insulin 2021 ·Pharmaceutics ·Aejin Lee, (unknown), Tao Lin, Shashi Bhushan Kumar, (unknown), (unknown), (unknown), Yuan Sun, Joana Ortega‐Anaya, Lianbo Yu, Julie C. Fitzgerald, A. Courtney DeVries, Randy J. Nelson, Zachary M. Weil, Rafael Jiménez‐Flores, Jon R. Parquette, Ouliana Ziouzenkova	3
7	Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing 2020 ·Molecular Cancer Research ·Russell Bonneville, (unknown), Michele R. Wing, Melanie A. Krook, Julie W. Reeser, Hui‐Zi Chen, (unknown), Eric Samorodnitsky, Amy Smith, Lianbo Yu, (unknown), (unknown), Sameek Roychowdhury	7
8	A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer 2019 ·Cancer Research ·Kalpana Deepa Priya Dorayappan, Miranda L. Gardner, Colin L. Hisey, Roman A. Zingarelli, (unknown), (unknown), Rajan Gogna, (unknown), John L. Hays, Derek J. Hansford, Michael A. Freitas, Lianbo Yu, David E. Cohn, Karuppaiyah Selvendiran	88
9	Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma 2019 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Nissar Ahmad Wani, Li Ding, Peng Hu, Juan M. Barajas, Lianbo Yu, Xiaoli Zhang, Samson T. Jacob, Wasif N. Khan, Xue‐Feng Bai, Anne M. Noonan, Kalpana Ghoshal	27
10	Rethinking Lupus Nephritis Classification on a Molecular Level 2019 ·Journal of Clinical Medicine ·Salem Almaani, Stephenie D. Prokopec, Jianying Zhang, Lianbo Yu, Carmen Ávila-Casado, Joan Wither, James W. Scholey, Valeria Albertón, Ana Malvar, Samir V. Parikh, Paul C. Boutros, Brad H. Rovin, Heather N. Reich	23
11	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON 2018 ·Cancer Immunology Research ·Zhiwei Hu, Rulong Shen, (unknown), Elizabeth L. McMichael, Lianbo Yu, Bhuvaneswari Ramaswamy, Cheryl A. London, Tian Xu, William E. Carson	33
12	Reprogramming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis 2018 ·Molecular Cancer Research ·Nissar Ahmad Wani, Bo Zhang, Kun‐Yu Teng, Juan M. Barajas, Tasneem Motiwala, (unknown), Lianbo Yu, Rafael Brüschweiler, Kalpana Ghoshal, Samson T. Jacob	32
13	Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 2017 ·Molecular Cancer Therapeutics ·Jharna Datta, Senthilkumar Damodaran, (unknown), (unknown), Jharna Miya, Lianbo Yu, (unknown), Eric Samorodnitsky, Michele R. Wing, Darshna Bhatt, John L. Hays, Julie W. Reeser, Sameek Roychowdhury	72
14	MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions 2017 ·Cancer Immunology Research ·Amanda R. Campbell, Megan Duggan, Lorena P. Suarez‐Kelly, (unknown), (unknown), Elizabeth L. McMichael, Prashant Trikha, Robin Parihar, (unknown), (unknown), Bryant C. Yung, Robert J. Lee, David H. Raulet, Susheela Tridandapani, Veronika Groh, Lianbo Yu, Vedat Yildiz, John C. Byrd, Michael A. Caligiuri, William E. Carson	15
15	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells 2016 ·Cancer Immunology Research ·(unknown), (unknown), Nikhil Gupta, Jeffrey A. Jones, Xiaokui Mo, Erin Hertlein, Lianbo Yu, Natarajan Muthusamy, John C. Byrd	13
16	Breast Cancer–Specific miR Signature Unique to Extracellular Vesicles Includes “microRNA-like” tRNA Fragments 2015 ·Molecular Cancer Research ·(unknown), Kitty Agarwal, D. Asthagiri, Lianbo Yu, Motoyasu Saji, Matthew D. Ringel, Michael E. Paulaitis	76
17	Extracellular Matrix Protein CCN1 Limits Oncolytic Efficacy in Glioma 2012 ·Cancer Research ·Amy Haseley, (unknown), Jeffrey Wojton, Lianbo Yu, Ji Young Yoo, Jianhua Yu, Kazuhiko Kurozumi, Joseph C. Glorioso, Michael A. Caligiuri, Balveen Kaur	51
18	Chondroitinase ABC I–Mediated Enhancement of Oncolytic Virus Spread and Antitumor Efficacy 2010 ·Clinical Cancer Research ·Nina Dmitrieva, Lianbo Yu, Mariano S. Viapiano, Timothy P. Cripe, E. Antonio Chiocca, Joseph C. Glorioso, Balveen Kaur	70
19	HIV-1 Tat RNA silencing suppressor activity is conserved across kingdoms and counteracts translational repression of HIV-1 2009 ·Proceedings of the National Academy of Sciences ·Shuiming Qian, Xuehua Zhong, Lianbo Yu, Biao Ding, Peter Haan, Kathleen Boris‐Lawrie	79
20	Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-α Compared with Immune Effector Cells 2007 ·Clinical Cancer Research ·Gregory B. Lesinski, John C. Trefry, (unknown), Sri Vidya Kondadasula, (unknown), Jason M. Zimmerer, Abhik Ray Chaudhury, Lianbo Yu, Xiaoli Zhang, (unknown), Michael J. Walker, William E. Carson	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact